Skip to content

One-quarter died on HIV treatment waiting list in South Africa's Free State province

ACTG 5202: No significant difference in time to failure between Kivexa and Truvada in patients with lower viral loads when paired with efavirenz or atazanavir

Even very low levels of pre-existing resistance increase risk of efavirenz failure

HIV treatment responses in everyday care matching clinical trial levels

Genetic marker predicts fat loss due to d4T in Thai patients

Adherence partners give short-term boost, but no long-term benefit, in Nigerian study

Subtle changes in immune system soon after HIV infection show who may benefit from earlier treatment

Low quality of life associated with poorer survival for patients taking HIV treatment

Starting HIV treatment reduces risk of death from all causes; additional benefits if treatment started sooner